Droxicam is an orally-active prodrug of piroxicam useful in the treatment of
spinal osteoarthritis. Although it has a pharmacological profile comparable to
piroxicam, droxicam's experimental ulcerogenic effect is ten times less. In animal
studies droxicam is also reported to have analgesic and antipyretic activities, with no
cardiovascular or respiratory effects.
Droxicam is a non-steroidal anti-inflammatory drug.
ChEBI: An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respe
tively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.
World Health Organization (WHO)
Droxicam is authorized to be marketed in many European
countries. Although droxicam is metabolized to piroxicam, it is considered that the risk of hepatic damage differs from that shown by other NSAIDs products,
including piroxicam.
